VAXART BIOSCIENCES INC - CLINICAL TRIAL PLANNING ACTIVITIES FOR A PHASE 2B CLINICAL TRIAL THAT COMPARES VAXART'S XBB VACCINE CANDIDATE TO AN MRNA COMPARATOR TO EVALUATE EFFICACY FOR SYMPTOMATIC AND ASYMPTOMATIC DISEASE, SYSTEMIC AND MUCOSAL IMMUNE INDUCTION, AND ADVERSE

On Feb 2, 2026, Department of Health and Human Services obligated $9,271,191 to VAXART BIOSCIENCES INC for clinical trial planning activities for a phase 2b clinical trial that compares vaxart's xbb vaccine candidate to an mrna comparator to evaluate efficacy for symptomatic and asymptomatic disease, syste…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in SOUTH SAN FRANCISCO, CA. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.